Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A case of interstitial pneumonia induced by rituximab therapy.

Literature DB >> 15765788

A case of interstitial pneumonia induced by rituximab therapy.

Junji Hiraga, Yasuhiro Kondoh, Hiroyuki Taniguchi, Tomohiro Kinoshita, Tomoki Naoe.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2005 PMID： 15765788 DOI： 10.1532/ijh97.04163

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

× No keyword cloud information.

6 in total

1. Interstitial pneumonitis related to rituximab therapy.

Authors: Catherine Burton; Richard Kaczmarski; Riaz Jan-Mohamed
Journal: N Engl J Med Date: 2003-06-26 Impact factor: 91.245

2. Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.

Authors: E Kurakawa; I Kasuga; S Ishizuka; T Yoshida; A Kunisawa; K Minemura; K Utsumi; K Ohyashiki
Journal: Jpn J Clin Oncol Date: 2001-06 Impact factor: 3.019

3. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.

Authors: Douglas L Riegert-Johnson; John A Godfrey; Jeffrey L Myers; Rolf D Hubmayr; William J Sandborn; Edward V Loftus
Journal: Inflamm Bowel Dis Date: 2002-05 Impact factor: 5.325

4. Circulating KL-6 levels in patients with drug induced pneumonitis.

Authors: H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno
Journal: Thorax Date: 2003-10 Impact factor: 9.139

5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Authors: P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire
Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544

Review 6. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.

Authors: Kensei Tobinai
Journal: Int J Hematol Date: 2002-12 Impact factor: 2.319

6 in total

1. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

Authors: Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri
Journal: Br J Clin Pharmacol Date: 2018-03-25 Impact factor: 4.335

A case of interstitial pneumonia induced by rituximab therapy.

1. Interstitial pneumonitis related to rituximab therapy.

2. Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.

3. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.

4. Circulating KL-6 levels in patients with drug induced pneumonitis.

5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Review 6. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.

1. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

2. Increased incidence of interstitial pneumonia by CHOP combined with rituximab.

Review 3. Anticancer therapy and lung injury: molecular mechanisms.

4. Rituximab-induced bronchiolitis obliterans organizing pneumonia.

5. Two cases of interstitial pneumonitis caused by rituximab therapy.

6. Acute respiratory distress syndrome after rituximab infusion.